Aspen Pharma Pty Ltd v H Lundbeck A/S

Link copied
Case Copied 26 min read

FEDERAL COURT OF AUSTRALIA

Aspen Pharma Pty Ltd v H Lundbeck A/S [2013] FCA 324

Citation: Aspen Pharma Pty Ltd v H Lundbeck A/S [2013] FCA 324
Appeal from: Aspen Pharma Pty Ltd and Ors and Commissioner of Patents and H Lundbeck (Joined Party) [2012] AATA 851
Parties: ASPEN PHARMA PTY LTD ACN 004 118 594, SANDOZ PTY LTD ACN 075 449 553, APOTEX PTY LTD ACN 096 916 148 and ALPHAPHARM PTY LTD ACN 002 359 739 v H LUNDBECK A/S  and COMMISSIONER OF PATENTS
File number: NSD 2236 of 2012
Judge: YATES J
Date of judgment: 9 April 2013
Catchwords: PRACTICE AND PROCEDURE – application for a stay of a decision of the Administrative Appeals Tribunal – whether a stay would be appropriate to secure the effectiveness of the hearing and determination of the appeal before the Court – principles relevant to determining whether a stay is appropriate – whether the appeal has some prospect of success – whether the first respondent would lose the benefit of earlier decisions in its favour – relevance of the undesirability of potential parallel proceedings before the Court and the Commissioner of Patents – relevance of potential costs to the applicants in anticipated proceedings before the Commissioner  
Legislation: Administrative Appeals Tribunal Act 1975 (Cth)
Patents Act 1990 (Cth)
Patents Regulations 1991 (Cth)
Cases cited: Alphapharm Pty Ltd v H Lundbeck A/S (2008) 76 IPR 618
Alphapharm Pty Limited & Ors v H. Lundbeck A/S [2011] APO 36; 92 IPR 628
Broadbent v Civil Aviation Safety Authority [1999] FCA 1871
Catena v Australian Securities and Investment Commission [2010] FCA 598
Citrus Queensland Pty Ltd v Sunstate Orchards Pty Ltd [2008] FCA 1867
H Lundbeck A/S v Alphapharm Pty Ltd (2009) 177 FCR 151
Hartnett v Migration Agents Registration Authority [2003] FCA 998
Minister of State for Education and Youth Affairs v Bracken (1984) 6 FCR 197
ReAspen Pharma Pty Ltd and Commissioner of Patents [2012] AATA 851
Secretary, Department of Families, Housing, Community Services and Indigenous Affairs v Mouratidis [2010] FCA 880
Theo v The Secretary, Department of Family Services [2004] FCA 1748
Date of hearing: 15 March 2013
Date of publication of reasons:  12 April 2013
Place: Sydney
Division: GENERAL DIVISION
Category: Catchwords
Number of paragraphs: 64
Counsel for the Applicants: Mr C Dimitriadis
Solicitor for the Applicants: King & Wood Mallesons
Counsel for the First Respondent: Mr R Niall SC
Solicitor for the First Respondent: Corrs Chambers Westgarth
Counsel for the Second Respondent: The Second Respondent was excused from attendance

IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 2236 of 2012

ON APPEAL FROM THE ADMINISTRATIVE APPEALS TRIBUNAL
BETWEEN:

ASPEN PHARMA PTY LTD ACN 004 118 594
First Applicant

SANDOZ PTY LTD ACN 075 449 553
Second Applicant

APOTEX PTY LTD ACN 096 916 148
Third Applicant

ALPHAPHARM PTY LTD ACN 002 359 739
Fourth Applicant

AND:

H LUNDBECK A/S
First Respondent

COMMISSIONER OF PATENTS
Second Respondent

JUDGE:

YATES J

DATE OF ORDER:

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Aspen Pharma Pty Ltd v H Lundbeck A/S and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2013] FCA 324
Decision Date

CaseChat Overview and Summary

The case of Aspen Pharma Pty Ltd v H Lundbeck A/S involves an application for a stay of the delegate’s decision, which was affirmed by the Administrative Appeals Tribunal (AAT). The first respondent opposes the granting of any stay. The Commissioner has not sought to be heard on the application. The dispute concerns the extension of the term of a standard patent for a pharmaceutical substance under the Patents Act. The applicants, Aspen Pharma Pty Ltd, sought an extension of the term of their patent, but their application was denied by the Commissioner. The applicants then appealed the decision to the AAT, which affirmed the Commissioner's decision. The applicants have now sought a stay of the AAT's decision pending the outcome of their appeal to the Federal Court.

The central legal issue in this case is whether the notice of appeal raises questions of law that are arguable and have a reasonable prospect of success. The applicants argue that the AAT erred in its interpretation of sections 223(2)(a) and 70(4) of the Patents Act and regulation 22.11(4)(b) of the Patents Regulations 1991. The first respondent contends that the appeal does not have good prospects of success and that the applicants have not demonstrated the likely quantum of costs that will be incurred if the stay is not granted. The court must balance the desirability of avoiding parallel proceedings against the potential for incurring unnecessary costs.

The court found that the questions of law raised by the applicants were arguable and had some prospect of success. The court was satisfied that the appeal had a reasonable prospect of success and that the applicants had demonstrated the potential for incurring unnecessary and irrecoverable costs if the stay was not granted. The court also noted that the costs of bringing an opposition proceeding should not be substantial and that the preconditions for an extension of term largely involve the fulfilment of straightforward requirements on the part of the patentee. The court concluded that the balance of convenience favoured the granting of a stay.

The court granted the applicants' application for a stay of the AAT's decision pending the outcome of their appeal to the Federal Court. The first respondent's opposition to the granting of a stay was rejected. The court ordered that the AAT's decision be stayed until the appeal to the Federal Court is determined or until further order of the court. The applicants were also granted leave to appeal to the Full Court.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

The matter for present determination is the applicants’ application for a stay of the delegate’s decision that was affirmed by the AAT. The first respondent opposes the granting of any stay. The Commissioner has not sought to be heard on the application. BACKGROUNDExtensions of term Part 3 of Chapter 6 of the Act provides that the term of a standard patent relating to a pharmaceutical substance can be extended. The patentee of such a patent may apply to the Commissioner for an extension of term if certain requirements are satisfied: s 70(1). The requirements are set out in s 70(2), (3) and (4). First, either or both of the following conditions must be satisfied:(a)one or more pharmaceutical substances per se must in substance be disclosed in the complete specification of the patent and in substance fall within the scope of the claim or claims of that specification;(b)one or more pharmaceutical substances when produced by a process that involves the use of recombinant DNA technology, must in substance be disclosed in the complete specification of the patent and in substance fall within the scope of the claim or claims of that specification: s 70(2). Secondly, both of the following conditions must be satisfied in relation to at least one of those pharmaceutical substances: (a)goods containing, or consisting of, the substance must be included in the Australian Register of Therapeutic Goods (the ARTG);(b)the period beginning on the date of the patent and ending on the first regulatory approval date for the substance must be at least five years: s 70(3). Thirdly, the term of the patent must not have been previously extended under Part 3 of Chapter 6 of the Act: s 70(4). Section 71 of the Act provides for the form in which such an application can be made and the time within which such an application can be brought. The time requirement is important in this matter. Section 71(2) provides: An application for an extension of the term of a standard patent must be made during the term of the patent and within 6 months after the latest of the following dates:(a) the date the patent was granted;(b)the date of commencement of the first inclusion in the Australian Register of Therapeutic Goods of goods that contain, or consist of, any of the pharmaceutical substances referred to in subsection 70(3);(c) the date of commencement of this section. The Commissioner must accept an application for an extension of term if satisfied that the requirements of s 70, and the form and time requirements of s 71, are satisfied in relation to the application: s 74(1). If the application is accepted, the Commissioner must publish a notice of acceptance in the Official Journal: s 74(2)(b). The Minister or any other person may, in accordance with the Patents Regulations 1991 (Cth) oppose the grant of an extension of term on the ground that the requirements of ss 70 and 71 are not satisfied. The grant of an extension cannot be opposed on any other ground: s 75(1). The patentee and any opponent may appeal to the Court against a decision of the Commissioner in respect of an extension of term: s 75(4). Such an appeal would be a hearing de novo.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

The first respondent also challenges a number of bases on which the appeal has been brought. It submits that, subject to two exceptions, the applicants’ notice of appeal does not raise questions of law. The two exceptions are questions 1 and 2, which raise, respectively, the proper construction of s 223(2)(a) (considered with s 223(11) of the Act and reg 22.11(4)(b) of the Regulations) and the proper construction of s 70(4) of the Act. Even so, it submits that these questions were correctly determined by the AAT in its favour. It submits that, although not unarguable, the appeal does not enjoy good prospects of success and that this is a relevant consideration in determining how the discretion should be exercised in the present application.CONSIDERATION The critical issue in the appeal is whether s 223(2)(a) of the Act, read in light of s 223(11) and reg 22.11(4)(b), confers the power to extend time for filing, during the term of the patent, an application for an extension of term under s 70(1) of the Act. I am satisfied, for the purposes of this application, that this question is raised as a question of law by the notice of appeal and that the construction for which the applicants contend is arguable. I am satisfied that the appeal has some prospect of success. In saying this, I do not wish to be taken as implying that, in my view, the construction favoured by the Commissioner and the AAT is wrong. It is a construction that is available, for the reasons expressed by the AAT. It will be a matter for the Full Court to determine the correctness of that construction. It is not necessary for me to discuss each and every one of the other questions that are said to arise on the appeal, beyond noting, in a summary way, that I am not persuaded that, considered cumulatively, those grounds substantially add to the applicants’ prospects of success in the appeal. It seems to me that the fate of the present application really rests in balancing the other considerations which the parties have advanced for and against the granting of a stay. At face value, the contention that there should not be parallel proceedings before the Commissioner while the appeal to this Court is pending, is persuasive. Absent other considerations, the taking of further steps in the extension of term application – dependent as that application is upon the proper exercise of the power under s 223(2)(a) of the Act – may be undesirable, to the extent that it is possible that unnecessary and irrecoverable costs will be incurred. However, the following matters should be noted. First, insofar as the applicants rely on prejudice to themselves, they have placed no evidence before the Court as to the likely quantum of the costs that will be incurred. Thus, their concerns find no material expression beyond the construct of their contention. I accept that if the anticipated opposition proceedings take their course, the steps which the applicants have identified will need to be taken and that, as a consequence, costs will be incurred. However, the preconditions for an extension of term largely involve the fulfilment of somewhat prosaic requirements on the part of the patentee which, normally, do not admit of significant debate. The costs of bringing an opposition proceeding should not be substantial.